Benchmark lowers Freshpet stock price target to $80 on weaker volume growth

Multiple analysts, including Benchmark, have significantly reduced price targets for Freshpet (FRPT) due to concerns over decelerating volume growth, attributing it to the high cost of fresh pet food and broader economic pressures impacting pet ownership expenses. Benchmark lowered its target to $80 from $95 while maintaining a Buy rating, despite FRPT reporting a 13% year-over-year revenue increase that slightly missed consensus, reflecting a challenging macroeconomic backdrop for consumer discretionary spending on premium pet products, which has contributed to the stock's 64% year-to-date decline and led to varied analyst outlooks from Buy to Sell.

Analysis

A consensus of analyst price target reductions for Freshpet (FRPT) underscores mounting concerns over decelerating volume growth, driven by macroeconomic pressures on consumer spending. Benchmark lowered its price target to $80 from $95, attributing the revision to slowing retail scanner data and challenges in converting households to the premium-priced fresh pet food category amid high inflation. This headwind is reflected in the company's recent performance, where a 13% year-over-year revenue increase to $265 million fell just short of the $268 million consensus estimate. Despite the top-line miss, the report noted stronger profitability metrics. The stock's 64% year-to-date decline has created a sharp division among analysts; while Benchmark and DA Davidson maintain 'Buy' ratings, citing long-term brand strength, UBS holds a 'Sell' rating with a $48 target, and JPMorgan initiated with a 'Neutral' rating. This wide dispersion in price targets, from $48 to $101, highlights significant uncertainty regarding Freshpet's ability to sustain its growth trajectory in the current economic environment versus its potential for being undervalued after the significant sell-off.

Key Decisions for Investors

• Investors with a long-term bullish view on the 'pet humanization' trend could consider the stock's 64% year-to-date decline a potential entry point, aligning with analysts who maintain 'Buy' ratings despite the near-term headwinds.
• Caution is warranted due to the confirmed slowdown in volume growth and divergent analyst opinions; the 'Sell' rating and $48 price target from UBS highlight significant downside risk if consumer discretionary spending remains weak.
• Monitor upcoming retail scanner data and corporate earnings closely for any stabilization in volume growth, as this is the primary metric driving the current debate and will be critical for the stock's future performance.